The table below shows Kiniksa Pharmaceuticals, Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$214.27M
$180.85M
$156.80M
$137.78M
$112.21M
$108.63M
Cost of revenue
$20.80M
$20.26M
$18.60M
$17.87M
$20.11M
$12.32M
Gross profit
-
-
-
-
-
-
R&D
$27.48M
$24.17M
$18.75M
$19.32M
$26.06M
$24.02M
KNSA annual revenue (10-K history)
Kiniksa Pharmaceuticals, Ltd. reported annual revenue of $677.56M for fiscal year 2025. That is up 60.1% from $423.24M in fiscal 2024. Over the 5 fiscal years shown, annual revenue grew from $38.54M (FY 2021) to $677.56M. Figures come from the company's audited annual reports as filed with the SEC.